There is no single “best” cream for skin cancer. The right topical treatment depends on the type of skin cancer, how deep it goes, and where it is on your body. Two prescription creams are FDA-approved for superficial basal cell carcinoma: fluorouracil (sold as Efudex) and imiquimod (sold as Aldara). For precancerous spots called actinic keratoses, you have additional options including a newer 5-day ointment called tirbanibulin. None of these are available over the counter, and none work on cancers that have grown beyond the skin’s surface.
Why Topical Creams Only Work on Surface-Level Cancers
This is the most important thing to understand before researching creams: topical treatments can only kill abnormal cells on or very near the skin’s surface. They cannot reach cancer that has grown deeper into the skin or spread to other areas. That’s why these creams are generally reserved for precancerous actinic keratoses and very superficial skin cancers, meaning cancers confined entirely to the outermost layer of skin.
For basal cell carcinomas that extend deeper, squamous cell carcinomas with any invasion, or melanoma, surgery remains the standard treatment. Your dermatologist will biopsy the spot first to determine exactly how deep the abnormal cells go before recommending a topical option.
Fluorouracil (5-FU) for Superficial Basal Cell Carcinoma
Fluorouracil cream at 5% concentration is the most widely recognized topical for both actinic keratoses and superficial basal cell carcinoma. It works by interfering with the DNA replication of rapidly dividing cells, essentially poisoning the abnormal cells while they try to grow. You apply it directly to the affected area twice daily.
In a clinical study of patients with biopsy-confirmed superficial basal cell carcinomas on the trunk or limbs, 5% fluorouracil achieved a 90% cure rate confirmed by tissue analysis. The average time to visible clearing was about 10.5 weeks, though treatment courses can run up to 12 weeks. Patients in the study reported good cosmetic outcomes and high satisfaction, which matters because this cream causes significant redness, crusting, and irritation during the treatment period. That reaction is expected and actually signals the cream is working.
The treatment area typically looks worse before it looks better. Skin becomes raw, inflamed, and sometimes painful for several weeks. Once you stop applying the cream, healing takes an additional two to four weeks. The payoff is avoiding a surgical scar, which makes fluorouracil especially appealing for large treatment areas or cosmetically sensitive spots.
Imiquimod for Basal Cell Carcinoma
Imiquimod takes a completely different approach. Rather than directly killing cancer cells, it activates your immune system to do the job. When applied to the skin, the cream triggers immune cells to recognize and attack abnormal tissue. It also directly promotes a self-destruct process in tumor cells by activating proteins that trigger cell death from the inside.
Because very little of the cream gets absorbed beyond the treatment site (less than 1% enters your bloodstream), side effects are mostly local: redness, swelling, crusting, and sometimes flu-like symptoms. The standard regimen for superficial basal cell carcinoma involves applying the cream five days per week for six weeks, though your dermatologist may adjust the schedule.
Imiquimod has also drawn interest for treating lentigo maligna, a very early form of melanoma that stays within the top layer of skin. Case series have reported response rates ranging from 67% to 100%, and some dermatologists use it after surgical excision as an extra safeguard. This use is not FDA-approved, however, and it’s only considered for lesions that haven’t invaded deeper tissue. It is never appropriate for invasive melanoma.
Creams for Actinic Keratosis (Precancerous Spots)
If your search is really about precancerous rough patches rather than confirmed skin cancer, you have more topical options. Actinic keratoses are the most common reason dermatologists prescribe these creams, since treating them early prevents potential progression to squamous cell carcinoma.
Fluorouracil
The same 5% fluorouracil cream used for superficial basal cell carcinoma is a workhorse for actinic keratoses. Treatment courses are typically shorter, often two to four weeks for the face. It’s particularly useful for “field treatment,” where you apply it to an entire sun-damaged area rather than individual spots, clearing both visible and not-yet-visible precancerous cells.
Tirbanibulin (Klisyri)
Tirbanibulin is the newest FDA-approved option, and its biggest advantage is the short treatment course: just five consecutive days of once-daily application. It’s approved specifically for actinic keratoses on the face or balding scalp. In two large clinical trials with over 700 patients, complete clearance of all lesions occurred in 44% to 54% of patients by day 57, compared to 5% to 13% with a placebo ointment. Partial clearance of 75% or more of lesions occurred in 68% to 76% of patients.
One notable limitation: the 12-month recurrence rate was 73%, meaning most patients who initially cleared saw some lesions return within a year. This doesn’t mean the treatment failed, since actinic keratoses develop from cumulative sun damage that continues to produce new spots. But it does mean tirbanibulin is better understood as a management tool than a one-time cure.
Diclofenac Sodium 3% Gel
Diclofenac gel is an anti-inflammatory treatment applied twice daily for 60 to 90 days. It’s gentler than fluorouracil, causing less dramatic skin reactions, but its clearance rates are also lower. In one study, using diclofenac gel for 90 days after an initial freezing treatment cleared 64% of targeted lesions completely, compared to 32% with freezing alone. It’s sometimes chosen for patients who can’t tolerate the intense inflammation of fluorouracil.
What Topical Creams Cannot Treat
No cream is appropriate for nodular basal cell carcinoma (the type that forms a raised bump extending into deeper skin), invasive squamous cell carcinoma, or any stage of invasive melanoma. Creams also aren’t recommended for lesions in certain locations. Tirbanibulin should be kept away from the eyes and mouth. Imiquimod studies for lentigo maligna have excluded lesions on the eyelids, lips, or mucous membranes.
The risk of using a topical cream on a deeper cancer is that the surface may appear to heal while abnormal cells continue growing underneath. This is why a biopsy confirming the cancer is truly superficial is essential before starting any cream-based treatment. If your dermatologist recommends surgery instead of a cream, it’s typically because the cancer extends too deep for topical treatment to reliably reach.
How to Choose Between Options
Your dermatologist will recommend a specific cream based on what the biopsy shows, but understanding the tradeoffs helps you have a more informed conversation. Fluorouracil has the longest track record and the highest cure rates for superficial basal cell carcinoma (around 90%), but it requires weeks of application and causes noticeable skin irritation. Imiquimod works through your immune system and may be preferred for certain locations or when your doctor wants to treat a wider margin around the visible lesion. For actinic keratoses, tirbanibulin offers the most convenient treatment course at five days, but with higher recurrence rates.
Cost, insurance coverage, and your tolerance for skin irritation all factor in. Some people prefer the shorter, more intense reaction of tirbanibulin over months of mild irritation from diclofenac. Others choose the proven reliability of fluorouracil despite the rougher treatment period. None of these creams are available without a prescription, and all require a confirmed diagnosis before starting.